SINGAPORE (Reuters) – Singapore has temporarily suspended the use of two influenza vaccines as a precaution after some people who received them in South Korea died, becoming one of the first countries to publicly announce the suspension of vaccine use.
South Korea said 48 people died on Saturday after taking flu vaccines, but said it would continue with the state vaccination program, as they found no direct link between the deaths and the vaccines.
No deaths associated with influenza vaccination have been reported in Singapore to date, but the decision to discontinue use of SKYCellflu Quadrivalent and VaxigripTetra was preventive, the ministry of health and the Health Sciences Authority (HAS) said in a statement late in the evening. of Sunday.
The HSA is in contact with South Korean authorities for more information, as they investigate to determine whether the deaths are related to influenza vaccination.
SKYCellflu Quadrivalent is manufactured by South Korea SK Bioscience and distributed locally by AJ Biologics, while VaxigripTetra is manufactured by Sanofi
and distributed locally by Sanofi Aventis.
Two other flu vaccines that were brought to Singapore for the northern hemisphere’s 2020/21 flu season could continue to be used, Singapore health officials said.